Title: Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor
Authors: Ge, TT
Phung, AL
Jhala, G
Trivedi, P
Principe, N
De George, DJ
Pappas, EG
Litwak, S
Sanz-Villanueva, L
Catterall, T
Fynch, S
Boon, L
Kay, TW
Chee, J
Krishnamurthy, B
Thomas, HE
Issue Year: 2022
Publisher WILEY
Series CLINICAL & TRANSLATIONAL IMMUNOLOGY:
Abstract Objectives: Immune checkpoint inhibitors have achieved clinical success in cancer treatment, but this treatment causes immune-related adverse events, including type 1 diabetes (T1D). Our aim was to test whether a JAK1/JAK2 inhibitor, effective at treating spontaneous autoimmune diabetes in nonobese diabetic (NOD) mice, can prevent diabetes secondary to PD-L1 blockade. Methods: Anti-PD-L1 antibody was injected into NOD mice to induce diabetes, and JAK1/JAK2 inhibitor LN3103801 was administered by oral gavage to prevent diabetes. Flow cytometry was used to study T cells and beta cells. Mesothelioma cells were inoculated into BALB/c mice to induce a transplantable tumour model. Results: Anti-PD-L1-induced diabetes was associated with increased immune cell infiltration in the islets and upregulated MHC class I on islet cells. Anti-PD-L1 administration significantly increased islet T cell proliferation and islet-specific CD8(+) T cell numbers in peripheral lymphoid organs. JAK1/JAK2 inhibitor treatment blocked IFN gamma-mediated MHC class I upregulation on beta cells and T cell proliferation mediated by cytokines that use the common gamma chain receptor. As a result, anti-PD-L1-induced diabetes was prevented by JAK1/JAK2 inhibitor administered before or after checkpoint inhibitor therapy. Diabetes was also reversed when the JAK1/JAK2 inhibitor was administered after the onset of anti-PD-L1-induced hyperglycaemia. Furthermore, JAK1/JAK2 inhibitor intervention after checkpoint inhibitors did not reverse or abrogate the antitumour effects in a transplantable tumour model. Conclusion: A JAK1/JAK2 inhibitor can prevent and reverse anti-PD-L1-induced diabetes by blocking IFN gamma and gamma c cytokine activities. Our study provides preclinical validation of JAK1/JAK2 inhibitor use in checkpoint inhibitor-induced diabetes.
URI: https://publications.svi.edu.au/publications/8495
Other Identifiers 10.1002/cti2.1425
Publication type Article